Blocking Anti-PD-L1 Antibody Sequences for T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting the PD-1 pathway have not been optimally commercialized to effectively enhance T-cell function and treat T cell dysfunctional disorders such as infections and tumors, highlighting a significant unmet medical need.
Innovation Solution
Development of an isolated, blocking anti-PD-L1 antibody with specific heavy and light chain variable region sequences, derived from human consensus framework sequences, designed to enhance T-cell function by antagonizing negative co-stimulatory signals and promoting cell-mediated immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 pathway is targeted to enhance T-cell function, then T-cell activation and immune response are improved, but therapeutic effectiveness and clinical application are limited due to lack of optimal commercialization
Solution Approach 1:
The patent optimizes antibody parameters including affinity (KD values), specificity, and functional activity to enhance therapeutic effectiveness. The anti-PD-L1 antibody is engineered with specific variable region sequences that bind PD-L1 with high affinity while maintaining selectivity, thereby improving T-cell activation and immune response without requiring complex manufacturing processes
Solution Approach 2:
The patent uses phage display technology to generate and screen antibody variants, creating optimized copies of the parent antibody with improved properties. This approach allows for systematic optimization of therapeutic effectiveness through iterative rounds of mutation and selection, while maintaining a streamlined development pathway that facilitates commercialization
2Measurement precision
If blocking anti-PD-L1 antibody is developed with specific sequence requirements, then binding specificity and affinity are improved, but development complexity and screening requirements increase
Solution Approach 1:
The patent divides the antibody development process into discrete segments: generating a library of variable region sequences, expressing them on phage particles, screening for binders, and optimizing selected clones. This segmentation allows for systematic improvement of binding specificity through controlled mutation and selection, while managing development complexity through modular workflow
Solution Approach 2:
The patent implements feedback loops in the antibody optimization process, where binding data from screening assays informs subsequent rounds of mutation and selection. This feedback mechanism enables iterative improvement of binding specificity and affinity, with each cycle building on previous results to progressively enhance antibody performance
3Productivity
If library screening is performed to identify specific antibody sequences, then antibody efficacy is improved, but time and resources for identification and characterization increase
Solution Approach 1:
The patent performs preliminary actions by pre-generating diverse libraries of variable region sequences with built-in diversity at key positions, and pre-establishing phage display systems for rapid screening. This preliminary preparation enables efficient identification of high-efficacy antibodies without requiring extensive de novo screening, thereby reducing time and resource requirements
Solution Approach 2:
The patent employs partial screening approaches by focusing on subsets of the library with most promising sequences, or by performing limited rounds of screening to identify a small number of high-performing clones. This partial action approach achieves sufficient antibody efficacy without requiring exhaustive screening of all library members, thereby reducing time and resource investment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-PD-L1 antibody enhances T-cell function, upregulates immune responses, and effectively treats T cell dysfunctional disorders including infections and tumors by increasing cytokine production and reducing pathogen levels or tumor growth.
Implementation Method 1
anti-PD-L1 antibody...block human PD-L1/PD-1 interaction
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application relates to anti-PD-Ll antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.